抗感染症ワクチン市場レポート：2023-2033

Anti-infective Vaccines Market Report 2023-2033

レポート詳細抗感染症ワクチン市場レポート 2023-2033年：本レポートは、業界とその基礎となるダイナミクスをより良く理解したい場合、新たな収益ポケットを目指している大手企業にとって貴重なも... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
Visiongain ヴィジョンゲイン社	2023年9月21日	GBP4,500 部署ライセンスライセンス・価格情報・注文方法はこちら	303	268	英語

※上記価格は部署ライセンス（Departmental licence）価格です。
その他の価格についてはデータリソースまでお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。

目次
図表リスト

サマリー

レポート詳細

抗感染症ワクチン市場レポート 2023-2033年：本レポートは、業界とその基礎となるダイナミクスをより良く理解したい場合、新たな収益ポケットを目指している大手企業にとって貴重なものとなるでしょう。異業種への進出や新規地域での既存事業の拡大を目指す企業にも有用です。

新型・再興感染症の増加が市場成長を牽引
世界的なアウトブレイクを引き起こしかねない新型感染症の急速な蔓延は大きな懸念材料である。これは、人々が野生生物に近づき、より長距離を移動し、かつてないほど混雑した地域に住むようになったことで起こっている。また、テロ活動の一環として、病気が意図的に人や動物、植物に移されることも懸念されている。COVID-19、SARS、MERS、エボラ出血熱、チクングニア、鳥インフルエンザ、豚インフルエンザ、ジカ熱は、検出された40の感染症のひとつである。将来のパンデミックやアウトブレイクは、COVID-19よりもはるかに壊滅的なものになると専門家は警告している。これらの伝染病が蔓延しつつあるため、今後数年間はワクチンの必要性が高まるだろう。その結果、研究開発への資金調達が増加し、新規ワクチンのパイプラインが充実し、幅広い人々のための代替ワクチンが増えることになる。これが市場を前進させることになります。

予防接種ワクチンの高コストが業界の成長を阻む可能性
ワクチンの開発には多額の費用がかかる。ワクチンは、他の医薬品とは異なり、特殊な設備や監視装置が必要であり、その結果、保管・流通コストが高くなる。保管や流通のためのインフラが不十分であれば、予防接種イニシアチブの効果や質が損なわれる可能性がある。試験管内の研究から販売までには10〜15年かかり、8億〜10億ドルのコストがかかる。さらに、ワクチン開発は成功率が低いため、企業は運営費の管理や初期資金の獲得に苦労することが多い。その結果、ワクチン開発と保管に関連するコスト増が市場拡大の障壁となっている。

市場調査レポートを購入する前にすべき質問とは？
- 抗感染症ワクチン市場はどのように進化しているのか？
- 何が抗感染症ワクチン市場を牽引し、阻害しているのか？
- 各抗感染症ワクチンサブマーケットセグメントは予測期間中にどのように成長し、2033年にはどれくらいの売上を占めるようになるのか？
- 2023年から2033年にかけて、各抗感染症ワクチンサブマーケットの市場シェアはどのように推移するのか？
- 2023年から2033年にかけて市場全体を牽引する主な要因は何か？
- 主要な抗感染症ワクチン市場はマクロ経済の動きに概ね追随するのか、それとも個々の国別市場が他を凌駕するのか？
- 2033年までに各国市場のシェアはどのように変化し、どの地域が2033年の市場をリードするのか？
- 主要プレーヤーは誰か、また予測期間中の見通しは？
- これら主要企業の抗感染症ワクチンプロジェクトとは？
- 2023年から2033年の間に、業界はどのように発展していくのか？現在および今後10年間に実施される抗感染症ワクチンプロジェクトにはどのような意味があるのでしょうか？
- 抗感染症ワクチン市場をさらに拡大するために、製品の商業化の必要性は高まっていますか？
- 抗感染症ワクチン市場はどこへ向かい、どのようにすれば市場の最前線に立てるのか？
- 新製品やサービスラインへの最適な投資方法とは？
- 企業を新たな成長軌道に乗せ、C-suiteに移行させるための重要な展望とは？

このことが現在、そして今後10年間の抗感染症ワクチン市場にどのような影響を与えるかを見極める必要がある：
- 3053ページに及ぶ本レポートは、112の表、157の図表を提供しています。
- 本レポートでは、業界における主要な有利分野をハイライトしているため、今すぐターゲットを絞ることができます。
- 本レポートには、世界、地域、国の売上と成長に関する詳細な分析が含まれています。
- 競合他社が成功した主なトレンド、変化、収益予測をハイライトしています。

本レポートは、抗感染性ワクチン市場が今後10年間でどのように発展していくのか、またCOVID-19の景気後退と回復の変動に合わせてどのように発展していくのかをお伝えします。この市場は、過去10年間のどの時点よりも今が重要である。

2033年までの予測やその他の分析から、商業的な展望が明らかになる
- 2033年までの収益予測に加え、直近の業績、成長率、市場シェアもご覧いただけます。
- ビジネスの展望と展開に関する独自の分析をご覧いただけます。
- 定性的分析（市場ダイナミクス、促進要因、機会、阻害要因、課題を含む）、コスト構造、抗感染性ワクチン価格上昇の影響、最近の動向をご覧いただけます。

本レポートには、COVID-19が業界と貴社にどのような影響を与えるかについてのデータ分析と貴重な洞察が含まれている。本レポートでは、COVID-19の4つの回収パターンとその影響、すなわち「V」、「L」、「W」、「U」について論じている。

レポート対象セグメント

ワクチンタイプ
- 季節性インフルエンザ
- 帯状疱疹
- Tdap含有/DTaP一次ワクチン
- 肺炎球菌結合型ワクチン (PCV)
- ヒトパピローマウイルス (HPV)
- ロタウイルス
- 水痘
- 髄膜炎菌
- その他のワクチン

応用タイプ
- ウイルス
- 細菌性

エンドユーザー
- 成人用ワクチン
- 小児用ワクチン
- 広範囲（総合）ワクチン

世界市場全体と各分野の収益予測に加え、5つの地域と24の主要国市場の収益予測も掲載している：

北米
- アメリカ
- カナダ

欧州
- ドイツ
- 英国
- フランス
- スペイン
- イタリア
- ロシア
- その他の欧州

アジア太平洋
- 中国
- 日本
- インド
- オーストラリア
- 韓国
- シンガポール
- その他のアジア太平洋地域

ラテンアメリカ
- ブラジル
- メキシコ
- アルゼンチン
- コロンビア
- その他のラテンアメリカ

MEA
- GCC
- 南アフリカ
- その他のMEA

本レポートには、2023年から2033年までの抗感染症ワクチン市場の主要企業のプロファイルも含まれており、これらの企業の事業のこのセグメントに焦点を当てている。

報告書に掲載されている主要企業
・ AstraZeneca
・ Bavarian Nordic
・ BioDiem
・ CSL
・ Emergent
・ Evotec SE
・ Merck KGaA
・ Mitsubishi Tanabe Pharma Corporation
・ Pfizer Inc.
・ Sanofi
・ Serum Institute of India Pvt. Ltd.
・ Sinovac
・ Valneva SE

2023年から2033年までの世界の抗感染性ワクチン市場全体の売上高（金額ベース）は、2023年に483億米ドルを突破する。2033年まで力強い収益成長を予測。当研究所では、最も大きな可能性を秘めた組織を特定している。彼らの能力、進歩、商業的展望を発見し、一歩先を行くお手伝いをします。

抗感染症ワクチン市場、2023-2033年レポートはどのように役立つのか？
まとめると、300ページを超えるこのレポートは、以下のような知識を提供する：

- 抗感染症ワクチン市場の2023年から2033年までの収益予測、ワクチンタイプ、アプリケーションタイプ、エンドユーザータイプの各予測を世界および地域レベルで掲載 - 業界の展望を発見し、投資と収益に最も有利な場所を見つけることができます。

- 5つの地域と24の主要国市場の2033年までの収益予測 - 北米、欧州、アジア太平洋、中南米、MEAの抗感染症ワクチン市場2023年から2033年までの市場予測をご覧ください。また、米国、カナダ、ドイツ、英国、フランス、スペイン、イタリア、ロシア、中国、インド、日本、オーストラリア、韓国、シンガポール、ブラジル、メキシコ、アルゼンチン、コロンビア、GCC、南アフリカ、その他主要経済圏の市場も予測しています。

- 既存企業および市場参入を目指す企業の展望 - 抗感染症ワクチン市場に関与する主要企業11社の企業プロファイルを含む、2023年から2033年までの市場。

独自の予測による定量的・定性的分析をご覧ください。私たちのレポートだけに含まれる情報を入手し、貴重なビジネスインテリジェンスで情報を得ることができます。

他にはない情報
私たちの新しいレポートがあれば、知識に遅れをとったり、チャンスを逃したりする可能性が低くなります。Visiongainの調査レポートが貴社の調査、分析、意思決定にどのように役立つかをご覧ください。Visiongainのこの調査レポートは、抗感染性ワクチン市場（2023年～2033年）の商業分析を必要とするすべての人、市場をリードする企業を対象としています。データ、トレンド、予測をご覧いただけます。

ページTOPに戻る

1 レポート概要
1.1 研究の目的
1.2 抗感染症ワクチン市場の紹介
1.3 本レポートの内容
1.4 本レポートを読むべき理由
1.5 本分析レポートが回答する主な質問
1.6 本レポートは誰のためのものか？
1.7 方法論
1.7.1 市場の定義
1.7.2 市場評価・予測手法
1.7.3 データの検証
1.7.3.1 一次調査
1.7.3.2 セカンダリーリサーチ
1.8 よくある質問（FAQ）
1.9 Visiongainの関連レポート
1.10 Visiongainについて

2 エグゼクティブ・サマリー

3 市場概要
3.1 主要な調査結果
3.2 市場ダイナミクス
3.2.1 市場牽引要因
3.2.1.1 パンデミック対策が抗感染症ワクチンの成長を牽引：グローバルヘルスにおけるパラダイムシフト
3.2.1.2 新興・再興感染症の流行増加
3.2.1.3 オーダーメイドのワクチン接種戦略に対する需要の高まりが市場拡大を促進
3.2.2 市場抑制要因
3.2.2.1 予防接種ワクチンの多額の費用が大きな障害となっている
3.2.2.2 未開発地域における抗感染性ワクチンへのアクセスの欠如
3.2.3 市場機会
3.2.3.1 政府、国際保健機関、ワクチン製造業者間の相乗的な協力関係
3.2.3.2 ワクチンおよび感染症研究の進展を促進する資金調達の増加
3.3 COVID-19インパクト分析
3.4 ポーターのファイブフォース分析
3.4.1 サプライヤーの交渉力
3.4.2 買い手の交渉力
3.4.3 競争相手のライバル関係
3.4.4 代替品による脅威
3.4.5 新規参入企業の脅威
3.5 PEST分析

4 抗感染症ワクチン市場分析：ワクチンタイプ別
4.1 主要調査結果
4.2 ワクチンタイプ別セグメント市場魅力度指標
4.3 ワクチンタイプ別抗感染症ワクチン市場規模の推定と予測
4.4 季節性インフルエンザ
4.4.1 2023〜2033年の地域別市場規模（US$ Million）
4.4.2 地域別市場シェア、2023年・2033年 (%)
4.5 帯状疱疹
4.5.1 2023〜2033年の地域別市場規模（US$ Million）
4.5.2 地域別市場シェア、2023年・2033年 (%)
4.6 TdaP含有/DTaPプライマリー
4.6.1 2023～2033年の地域別市場規模（US$ Million）
4.6.2 地域別市場シェア、2023年・2033年 (%)
4.7 肺炎球菌結合型ワクチン（PCV）
4.7.1 2023～2033年の地域別市場規模（US$ Million）
4.7.2 地域別市場シェア、2023年・2033年 (%)
4.8 ヒトパピローマウイルス（HPV）
4.8.1 2023〜2033年の地域別市場規模（US$ Million）
4.8.2 地域別市場シェア、2023年・2033年 (%)
4.9 ロタウイルス
4.9.1 2023〜2033年の地域別市場規模（US$ Million）
4.9.2 地域別市場シェア、2023年・2033年 (%)
4.10 水痘
4.10.1 2023～2033年の地域別市場規模（US$ Million）
4.10.2 地域別市場シェア、2023年・2033年 (%)
4.11 髄膜炎菌
4.11.1 2023～2033年の地域別市場規模（US$ Million）
4.11.2 地域別市場シェア、2023年・2033年 (%)
4.12 その他のワクチン
4.12.1 2023～2033年の地域別市場規模（US$ Million）
4.12.2 地域別市場シェア、2023年・2033年 (%)

5 抗感染症ワクチンの市場分析：用途タイプ別
5.1 主要な調査結果
5.2 用途タイプ別セグメント市場魅力度指数
5.3 用途タイプ別抗感染症ワクチン市場規模の推定と予測
5.4 ウイルス
5.4.1 2023〜2033年の地域別市場規模（US$ Million）
5.4.2 地域別市場シェア、2023年・2033年 (%)
5.5 細菌
5.5.1 2023～2033年の地域別市場規模（US$ Million）
5.5.2 地域別市場シェア、2023年・2033年 (%)

6 抗感染症ワクチン市場分析：エンドユーザー別
6.1 主要調査結果
6.2 エンドユーザー別セグメント市場魅力度指数
6.3 エンドユーザー別抗感染症ワクチン市場規模推定と予測
6.4 成人用ワクチン
6.4.1 2023〜2033年の地域別市場規模（US$ Million）
6.4.2 地域別市場シェア、2023年・2033年 (%)
6.5 小児用ワクチン
6.5.1 2023〜2033年の地域別市場規模（US$ Million）
6.5.2 地域別市場シェア、2023年・2033年 (%)
6.6 広範囲（総合）ワクチン
6.6.1 2023〜2033年の地域別市場規模（US$ Million）
6.6.2 地域別市場シェア、2023年・2033年 (%)

7 抗感染症ワクチン市場分析：地域別
7.1 主要な調査結果
7.2 地域別市場規模の推定と予測

8 北米の抗感染症ワクチン市場分析
8.1 主要な調査結果
8.2 北米の抗感染症ワクチン市場魅力度指数
8.3 北米の国別抗感染症ワクチン市場、2023年、2028年、2033年（US$ Million）
8.4 北米の抗感染症ワクチン市場規模推定と予測：国別
8.5 北米の抗感染症ワクチン市場規模推定と予測：ワクチンタイプ別
8.6 北米の抗感染症ワクチン市場規模推定と予測：用途タイプ別
8.7 北米の抗感染症ワクチン市場規模推定と予測：エンドユーザー別
8.8 アメリカの抗感染症ワクチン市場分析
8.9 カナダの抗感染症ワクチン市場分析

9 欧州の抗感染症ワクチン市場分析
9.1 主要な調査結果
9.2 欧州抗感染症ワクチン市場魅力度指数
9.3 欧州の抗感染症ワクチン国別市場、2023年、2028年、2033年（US$ Million）
9.4 欧州の抗感染症ワクチン市場規模推定と予測：国別
9.5 欧州の抗感染症ワクチン市場規模推定と予測：ワクチンタイプ別
9.6 欧州の抗感染症ワクチン市場規模推定と予測：用途タイプ別
9.7 欧州の抗感染症ワクチン市場規模推定と予測：エンドユーザー別
9.8 ドイツの抗感染症ワクチン市場分析
9.9 フランスの抗感染症ワクチン市場分析
9.10 イギリスの抗感染症ワクチン市場分析
9.11 イタリアの抗感染症ワクチン市場分析
9.12 スペインの抗感染症ワクチン市場分析
9.13 ロシアの抗感染症ワクチン市場分析
9.14 その他の欧州の抗感染症ワクチン市場分析

10 アジア太平洋地域の抗感染症ワクチン市場分析
10.1 主要な調査結果
10.2 アジア太平洋地域の抗感染症ワクチン市場魅力度指数
10.3 アジア太平洋地域の抗感染症ワクチン国別市場：2023年、2028年、2033年（US$ Million）
10.4 アジア太平洋地域の抗感染症ワクチン市場規模推定と予測：国別
10.5 アジア太平洋地域の抗感染症ワクチン市場規模推定と予測：ワクチンタイプ
10.6 アジア太平洋地域の抗感染症ワクチン市場規模推定と予測：用途タイプ別
10.7 アジア太平洋地域の抗感染症ワクチン市場規模推定と予測：エンドユーザー別
10.8 日本の抗感染症ワクチン市場分析
10.9 中国の抗感染症ワクチン市場分析
10.10 インドの抗感染症ワクチン市場分析
10.11 オーストラリアの抗感染症ワクチン市場分析
10.12 韓国の抗感染症ワクチン市場分析
10.13 シンガポールの抗感染症ワクチン市場の分析
10.14 その他のアジア太平洋地域の抗感染症ワクチン市場分析

11 ラテンアメリカの抗感染症ワクチン市場分析
11.1 主要な調査結果
11.2 ラテンアメリカの抗感染症ワクチン市場魅力度指数
11.3 ラテンアメリカの抗感染症ワクチン国別市場、2023年、2028年、2033年（US$ Million）
11.4 ラテンアメリカの抗感染症ワクチン市場規模推定と予測：国別
11.5 ラテンアメリカの抗感染症ワクチン市場規模推定と予測：ワクチンタイプ別
11.6 ラテンアメリカの抗感染症ワクチン市場規模推定と予測：用途タイプ別
11.7 ラテンアメリカの抗感染症ワクチン市場規模推定と予測：エンドユーザー別
11.8 ブラジルの抗感染症ワクチン市場分析
11.9 メキシコの抗感染症ワクチン市場分析
11.10 アルゼンチンの抗感染症ワクチン市場分析
11.11 コロンビアの抗感染症ワクチン市場分析
11.12 その他のラテンアメリカの抗感染症ワクチン市場分析

12 MEAの抗感染症ワクチン市場分析
12.1 主要な調査結果
12.2 MEAの抗感染性ワクチン市場魅力度指数
12.3 MEAの抗感染症ワクチン国別市場：2023年、2028年、2033年（US$ Million）
12.4 MEAの抗感染症ワクチン市場規模推定と予測：国別
12.5 MEAの抗感染症ワクチン市場規模推定と予測：ワクチンタイプ別
12.6 MEAの抗感染症ワクチン市場規模推定と予測：用途タイプ別
12.7 MEAの抗感染症ワクチン市場規模推定と予測：エンドユーザー別
12.8 GCCの抗感染症ワクチン市場分析
12.9 南アフリカの抗感染症ワクチン市場分析
12.10 その他のMEAの抗感染症ワクチン市場分析

13 主要企業のプロフィール
13.1 競争環境、2022年
13.2 戦略的展望
13.1 Pfizer Inc.
13.1.1 会社概要
13.1.2 会社概要
13.1.3 財務分析
13.1.3.1 純収入、2017-2022年
13.1.3.2 R＆D、2017-2022年
13.1.3.3 地域市場シェア、2022年
13.1.4 製品ベンチマーク
13.1.5 戦略的展望
13.2 AstraZeneca
13.2.1 会社概要
13.2.2 会社概要
13.2.3 財務分析
13.2.3.1 純収入、2017-2022年
13.2.3.2 R＆D、2017-2022年
13.2.3.3 地域市場シェア、2022年
13.2.4 製品ベンチマーク
13.2.5 戦略的展望
13.3 Bavarian Nordic
13.3.1 会社概要
13.3.2 会社概要
13.3.3 財務分析
13.3.3.1 純収入、2017-2022年
13.3.3.2 売上高、2017-2022年
13.3.3.3 地域市場シェア、2022年
13.3.4 製品ベンチマーク
13.3.5 戦略的展望
13.4 Serum Institute of India Pvt.
13.4.1 会社概要
13.4.2 会社概要
13.4.3 製品ベンチマーク
13.4.4 戦略的展望
13.5 BioDiem
13.5.1 会社概要
13.5.2 会社概要
13.5.3 製品ベンチマーク
13.6 Evotec SE
13.6.1 会社概要
13.6.2 会社概要
13.6.3 財務分析
13.6.3.1 純収入、2017-2022年
13.6.3.2 R＆D、2017-2022年
13.6.3.3 地域市場シェア、2022年
13.6.4 製品ベンチマーク
13.6.5 戦略的展望
13.7 Sinovac
13.7.1 会社概要
13.7.2 会社概要
13.7.3 財務分析
13.7.3.1 純収入、2017-2022年
13.7.3.2 売上高、2017-2022年
13.7.4 製品ベンチマーク
13.7.5 戦略的展望
13.8 Sanofi
13.8.1 会社概要
13.8.2 会社概要
13.8.3 製品ベンチマーク
13.8.4 戦略的展望
13.9 Merck KGaA
13.9.1 会社概要
13.9.2 会社概要
13.9.3 財務分析
13.9.3.1 純収入、2017-2022年
13.9.3.2 R＆D、2017年〜2022年
13.9.3.3 地域市場シェア、2022年
13.9.4 製品ベンチマーク
13.9.5 戦略的展望
13.10 CSL
13.10.1 会社概要
13.10.2 会社概要
13.10.3 財務分析
13.10.3.1 純収入、2017-2022年
13.10.3.2 R＆D、2017年〜2022年
13.10.3.3 地域市場シェア、2022年
13.10.4 製品ベンチマーク
13.10.5 戦略的展望
13.11 Emergent
13.11.1 会社概要
13.11.2 会社概要
13.11.3 財務分析
13.11.3.1 純収入（2017-2022年
13.11.3.2 売上高、2017-2022年
13.11.4 製品ベンチマーク
13.11.5 戦略的展望
13.12 Mitsubishi Tanabe Pharma Corporation
13.12.1 会社概要
13.12.2 会社概要
13.12.3 製品ベンチマーク
13.12.4 戦略的展望
13.13 GSK plc
13.13.1 会社概要
13.13.2 会社概要
13.13.3 財務分析
13.13.3.1 純収入、2017-2022年
13.13.3.2 売上高、2017-2022年
13.13.3.3 地域市場シェア、2022年
13.13.4 製品ベンチマーク
13.13.5 戦略的展望
13.14 Valneva SE
13.14.1 会社概要
13.14.2 会社概要
13.14.3 財務分析
13.14.3.1 純収入、2017-2022年
13.14.3.2 R＆D、2017-2022年
13.14.3.3 地域市場シェア、2022年
13.14.4 製品ベンチマーク
13.14.5 戦略的展望
13.15 Novavax
13.15.1 会社概要
13.15.2 会社概要
13.15.3 財務分析
13.15.3.1 純収入、2017-2022年
13.15.3.2 R＆D、2017-2022年
13.15.3.3 地域市場シェア、2022年
13.15.4 製品ベンチマーク
13.15.5 戦略的展望

14 結論と提言
14.1 Visiongainからの結びの言葉
14.2 市場プレイヤーへの提言

ページTOPに戻る

図表リスト

表の一覧
Table 1 Anti-infective Vaccines Market Snapshot, 2023 & 2033 (US$ Million, CAGR %)
Table 2 Anti-infective Vaccines Market Forecast by Region 2023-2033 (US$ Million, AGR%, CAGR%): "V" Shaped Recovery
Table 3 Anti-infective Vaccines Market Forecast by Region 2023-2033 (US$ Million, AGR%, CAGR%): "U" Shaped Recovery
Table 4 Anti-infective Vaccines Market Forecast by Region 2023-2033 (US$ Million, AGR%, CAGR%): "W" Shaped Recovery
Table 5 Anti-infective Vaccines Market Forecast by Region 2023-2033 (US$ Million, AGR%, CAGR%): "L" Shaped Recovery
Table 6 Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 7 Seasonal Influenza Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 8 Shingles Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 9 TdaP Containing/ DTaP Primary Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 10 Pneumococcal Conjugate Vaccine (PCV) Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 11 Human Papillomavirus (HPV) Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 12 Rotavirus Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 13 Varicella Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 14 Meningococcal Vaccine Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 15 Other Vaccine Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 16 Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 17 Viral Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 18 Bacterial Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 19 Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 20 Adult Vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 21 Paediatric Vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 22 Wide-ranging (comprehensive) vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 23 Anti-infective Vaccines Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 24 North America Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 25 North America Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 26 North America Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 27 North America Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 28 U.S. Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 29 Canada Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 30 Europe Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR %)
Table 31 Europe Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 32 Europe Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 33 Europe Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 34 Germany Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 35 France Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 36 UK Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 37 Italy Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 38 Spain Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 39 Russia Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 40 Rest of Europe Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 41 Asia Pacific Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 42 Asia Pacific Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 43 Asia Pacific Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 44 Asia Pacific Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 45 Japan Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 46 China Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 47 India Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 48 Australia Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 49 South Korea Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 50 Singapore Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 51 Rest of Asia Pacific Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 52 Latin America Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 53 Latin America Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 54 Latin America Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 55 Latin America Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 56 Brazil Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 57 Mexico Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 58 Argentina Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 59 Colombia Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 60 Rest of Latin America Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 61 MEA Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 62 MEA Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 63 MEA Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 64 MEA Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 65 GCC Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 66 South Africa Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 67 Rest of MEA Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 68 Strategic Outlook
Table 69 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 70 Pfizer Inc.: Product Benchmarking
Table 71 Pfizer: Strategic Outlook
Table 72 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 73 AstraZeneca: Product Benchmarking
Table 74 AstraZeneca: Strategic Outlook
Table 75 Bavarian Nordic: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 76 Bavarian Nordic: Product Benchmarking
Table 77 Bavarian Nordic: Strategic Outlook
Table 78 Serum Institute of India Pvt. Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 79 Serum Institute of India Pvt. Ltd.: Product Benchmarking
Table 80 Serum Institute of India Pvt. Ltd.: Strategic Outlook
Table 81 BioDiem: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 82 BioDiem: Product Benchmarking
Table 83 Evotec SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 84 Evotec SE: Product Benchmarking
Table 85 Evotec SE: Strategic Outlook
Table 86 Sinovac: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 87 Sinovac: Product Benchmarking
Table 88 Sinovac: Strategic Outlook
Table 89 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 90 Sanofi: Product Benchmarking
Table 91 Sanofi: Strategic Outlook
Table 92 Merck KGaA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 Merck KGaA: Product Benchmarking
Table 94 Merck: Strategic Outlook
Table 95 CSL: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 CSL: Product Benchmarking
Table 97 CSL: Strategic Outlook
Table 98 Emergent: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 99 Emergent: Product Benchmarking
Table 100 Emergent: Strategic Outlook
Table 101 Mitsubishi Tanabe Pharma Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 102 Mitsubishi Tanabe Pharma Corporation: Product Benchmarking
Table 103 Mitsubishi Tanabe Pharma Corporation: Strategic Outlook
Table 104 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 GSK plc: Product Benchmarking
Table 106 GSK: Strategic Outlook
Table 107 Valneva SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 108 Valneva SE: Product Benchmarking
Table 109 Valneva SE: Strategic Outlook
Table 110 Novavax: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 111 Novavax: Product Benchmarking
Table 112 Novavax: Strategic Outlook

図の一覧
Figure 1 Anti-infective Vaccines Market Segmentation
Figure 2 Anti-infective Vaccines Market by Vaccine Type: Market Attractiveness Index
Figure 3 Anti-infective Vaccines Market by Application Type: Market Attractiveness Index
Figure 4 Anti-infective Vaccines Market by End-users: Market Attractiveness Index
Figure 5 Anti-infective Vaccines Market Attractiveness Index by Region
Figure 6 Anti-infective Vaccines Market: Market Dynamics
Figure 7 Anti-infective Vaccines Market by Region, 2023-2033 (US$ Million, AGR %): “V” Shaped Recovery
Figure 8 Anti-infective Vaccines Market by Region, 2023-2033 (US$ Million, AGR %): “U” Shaped Recovery
Figure 9 Anti-infective Vaccines Market by Region, 2023-2033 (US$ Million, AGR %): “W” Shaped Recovery
Figure 10 Anti-infective Vaccines Market by Region, 2023-2033 (US$ Million, AGR %): “L” Shaped Recovery
Figure 11 Anti-infective Vaccines Market: Porter’s Five Forces Analysis
Figure 12 Anti-infective Vaccines Market: PEST Analysis
Figure 13 Anti-infective Vaccines Market by Vaccine Type: Market Attractiveness Index
Figure 14 Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
Figure 15 Anti-infective Vaccines Market Share Forecast by Vaccine Type, 2023, 2028, 2033 (%)
Figure 16 Seasonal Influenza Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 17 Seasonal Influenza Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 18 Shingles Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 19 Shingles Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 20 TdaP Containing/ DTaP Primary Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 21 TdaP Containing/ DTaP Primary Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 22 Pneumococcal Conjugate Vaccine (PCV) Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 23 Pneumococcal Conjugate Vaccine (PCV) Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 24 Human Papillomavirus (HPV) Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 25 Human Papillomavirus (HPV) Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 26 Rotavirus Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 27 Rotavirus Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 28 Varicella Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 29 Varicella Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 30 Meningococcal Vaccine Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 31 Meningococcal Vaccine Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 32 Other Vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 33 Other Vaccines Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 34 Anti-infective Vaccines Market by Application Type: Market Attractiveness Index
Figure 35 Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR %)
Figure 36 Anti-infective Vaccines Market Share Forecast by Application Type, 2023, 2028, 2033 (%)
Figure 37 Viral Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 38 Viral Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 39 Bacterial Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 40 Bacterial Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 41 Anti-infective Vaccines Market by End-users: Market Attractiveness Index
Figure 42 Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
Figure 43 Anti-infective Vaccines Market Share Forecast by End-users, 2023, 2028, 2033 (%)
Figure 44 Adult Vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 45 Adult Vaccines Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 46 Paediatric Vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 47 Paediatric Vaccines Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 48 Wide-ranging (comprehensive) vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 49 Wide-ranging comprehensive vaccines Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 50 Anti-infective Vaccines Market Forecast by Region 2023 and 2033 (Revenue, CAGR%)
Figure 51 Anti-infective Vaccines Market Share Forecast by Region 2023, 2028, 2033 (%)
Figure 52 Anti-infective Vaccines Market by Region, 2023-2033 (US$ Million, AGR %)
Figure 53 North America Anti-infective Vaccines Market Attractiveness Index
Figure 54 North America Anti-infective Vaccines Market by Region, 2023, 2028 & 2033 (US$ Million)
Figure 55 North America Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
Figure 56 North America Anti-infective Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
Figure 57 North America Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
Figure 58 North America Anti-infective Vaccines Market Share Forecast by Vaccine Type, 2023 & 2033 (%)
Figure 59 North America Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR %)
Figure 60 North America Anti-infective Vaccines Market Share Forecast by Application Type, 2023 & 2033 (%)
Figure 61 North America Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
Figure 62 North America Anti-infective Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
Figure 63 U.S. Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 64 Canada Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 65 Europe Anti-infective Vaccines Market Attractiveness Index
Figure 66 Europe Anti-infective Vaccines Market by Region, 2023, 2028 & 2033 (US$ Million)
Figure 67 Europe Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
Figure 68 Europe Anti-infective Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
Figure 69 Europe Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
Figure 70 Europe Anti-infective Vaccines Market Share Forecast by Vaccine Type, 2023 & 2033 (%)
Figure 71 Europe Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR %)
Figure 72 Europe Anti-infective Vaccines Market Share Forecast by Application Type, 2023 & 2033 (%)
Figure 73 Europe Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
Figure 74 Europe Anti-infective Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
Figure 75 Germany Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 76 France Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 77 UK Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 78 Italy Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 79 Spain Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 80 Russia Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 81 Rest of Europe Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 82 Asia Pacific Anti-infective Vaccines Market Attractiveness Index
Figure 83 Asia Pacific Anti-infective Vaccines Market by Region, 2023, 2028 & 2033 (US$ Million)
Figure 84 Asia Pacific Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
Figure 85 Asia Pacific Anti-infective Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
Figure 86 Asia Pacific Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
Figure 87 Asia Pacific Anti-infective Vaccines Market Share Forecast by Vaccine Type, 2023 & 2033 (%)
Figure 88 Asia Pacific Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR %)
Figure 89 Asia Pacific Anti-infective Vaccines Market Share Forecast by Application Type, 2023 & 2033 (%)
Figure 90 Asia Pacific Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
Figure 91 Asia Pacific Anti-infective Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
Figure 92 Japan Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 93 China Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 94 India Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 95 Australia Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 96 South Korea Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 97 Singapore Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 98 Rest of Asia Pacific Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 99 Latin America Anti-infective Vaccines Market Attractiveness Index
Figure 100 Latin America Anti-infective Vaccines Market by Region, 2023, 2028 & 2033 (US$ Million)
Figure 101 Latin America Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
Figure 102 Latin America Anti-infective Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
Figure 103 Latin America Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
Figure 104 Latin America Anti-infective Vaccines Market Share Forecast by Vaccine Type, 2023 & 2033 (%)
Figure 105 Latin America Anti-infective Vaccines Market Forecast by Usage Type, 2023-2033 (US$ Million, AGR %)
Figure 106 Latin America Anti-infective Vaccines Market Share Forecast by Application Type, 2023 & 2033 (%)
Figure 107 Latin America Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
Figure 108 Latin America Anti-infective Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
Figure 109 Brazil Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 110 Mexico Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 111 Argentina Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 112 Colombia Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 113 Rest of Latin America Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 114 MEA Anti-infective Vaccines Market Attractiveness Index
Figure 115 MEA Anti-infective Vaccines Market by Region, 2023, 2028 & 2033 (US$ Million)
Figure 116 MEA Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
Figure 117 MEA Anti-infective Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
Figure 118 MEA Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
Figure 119 MEA Anti-infective Vaccines Market Share Forecast by Vaccine Type, 2023 & 2033 (%)
Figure 120 MEA Anti-infective Vaccines Market Forecast by Usage Type, 2023-2033 (US$ Million, AGR %)
Figure 121 MEA Anti-infective Vaccines Market Share Forecast by Application Type, 2023 & 2033 (%)
Figure 122 MEA Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
Figure 123 MEA Anti-infective Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
Figure 124 GCC Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 125 South Africa Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 126 Rest of MEA Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 127 Pfizer Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 128 Pfizer Inc.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 129 Pfizer Inc.: Regional Market Shares, 2022
Figure 130 AstraZeneca: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 131 AstraZeneca: R&D, 2017-2022 (US$ Million, AGR%)
Figure 132 AstraZeneca: Regional Market Shares, 2022
Figure 133 Bavarian Nordic: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 134 Bavarian Nordic: R&D, 2017-2022 (US$ Million, AGR%)
Figure 135 AstraZeneca: Regional Market Shares, 2022
Figure 136 Evotec SE: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 137 Evotec SE: R&D, 2017-2022 (US$ Million, AGR%)
Figure 138 Evotec: Regional Market Shares, 2022
Figure 139 Sinovac: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 140 Sinovac: R&D, 2017-2022 (US$ Million, AGR%)
Figure 141 Merck KGaA: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 142 Merck KGaA: R&D, 2017-2022 (US$ Million, AGR%)
Figure 143 Merck KGaA: Regional Market Shares, 2022
Figure 144 CSL: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 145 CSL: R&D, 2017-2022 (US$ Million, AGR%)
Figure 146 CSL: Regional Market Shares, 2022
Figure 147 Emergent: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 148 Emergent: R&D, 2017-2022 (US$ Million, AGR%)
Figure 149 GSK plc: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 150 GSK plc: R&D, 2017-2022 (US$ Million, AGR%)
Figure 151 GSK plc: Regional Market Shares, 2022
Figure 152 Valneva SE: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 153 Valneva SE: R&D, 2017-2022 (US$ Million, AGR%)
Figure 154 Valneva SE: Regional Market Shares, 2022
Figure 155 Novavax: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 156 Novavax: R&D, 2017-2022 (US$ Million, AGR%)
Figure 157 Novavax: Regional Market Shares, 2022

ページTOPに戻る

Table of Contents
List of Tables/Graphs

Summary

Report Details

The Anti-infective Vaccines Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increased Occurrence of New and Re-emerging Infectious Illnesses Driving Market Growth
The rapid spread of novel infectious illnesses, which can lead to global outbreaks, is a big concern. This is happening as people get closer to wild creatures, travel longer distances, and live in more congested regions than ever before. There is also concern that diseases may be deliberately transferred to people, animals, or plants as part of terrorist activities. COVID-19, SARS, MERS, Ebola, chikungunya, avian flu, swine flu, and Zika are among the 40 infectious diseases detected. Future pandemics and outbreaks, experts warn, could be much more catastrophic than COVID-19. Because these contagious diseases are becoming more widespread, there will be a higher need for vaccines in the coming years. This will result in increased financing for R&D, a robust pipeline of novel vaccines, and more alternatives for a wide spectrum of people. This will propel the market forward.

High Cost of Immunisation Vaccines Likely to Challenge Industry Growth
The development of a vaccine is an expensive process. Vaccines, unlike other pharmaceutical items, necessitate specialised equipment and monitoring devices, resulting in greater storage and distribution costs. Inadequate infrastructure for storage and distribution may jeopardise the effectiveness and quality of immunisation initiatives. The process from in vitro research to marketing takes 10-15 years and costs between $800 million and $1 billion. Furthermore, because vaccine development has a poor success rate, firms frequently struggle with managing operational expenses and attracting initial finance. As a result, the increased costs associated with vaccine development and storage are acting as a barrier to market expansion.

What Questions Should You Ask before Buying a Market Research Report?
• How is the anti-infective vaccines market evolving?
• What is driving and restraining the anti-infective vaccines market?
• How will each anti-infective vaccines submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each anti-infective vaccines submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading anti-infective vaccines markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the anti-infective vaccines projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of anti-infective vaccines projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the anti-infective vaccines market?
• Where is the anti-infective vaccines market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the anti-infective vaccines market today, and over the next 10 years:
• Our 3053page report provides 112 tables, 157 charts /graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the anti-infective vaccines market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising anti-infective vaccines prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Vaccine Type
• Seasonal Influenza
• Shingles
• Tdap containing /DTaP Primary Vaccine
• Pneumococcal Conjugate Vaccine (PCV)
• Human Papillomavirus (HPV)
• Rotavirus
• Varicella
• Meningococcal
• Other Vaccines

Application Type
• Viral
• Bacterial

End-users
• Adult Vaccines
• Pediatric Vaccines
• Wide Ranging (Comprehensive) Vaccines

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 24 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of Latin America

MEA
• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Anti-infective Vaccines Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies profiled in the report
• AstraZeneca
• Bavarian Nordic
• BioDiem
• CSL
• Emergent
• Evotec SE
• Merck KGaA
• Mitsubishi Tanabe Pharma Corporation
• Pfizer Inc.
• Sanofi
• Serum Institute of India Pvt. Ltd.
• Sinovac
• Valneva SE

Overall world revenue for anti-infective vaccines market, 2023 to 2033 in terms of value the market will surpass US$48,300 million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Anti-infective Vaccines Market, 2023 to 2033 report help you?
In summary, our 300+ page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Anti-infective Vaccines, 2023 to 2033 Market, with forecasts for vaccine types, application types, and end-users types, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2033 for five regional and 24 key national markets – See forecasts for the Anti-infective Vaccines Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Germany, UK, France, Spain, Italy, Russia, China, India, Japan, Australia, South Korea, Singapore, Brazil, Mexico, Argentina, Colombia, GCC, South Africa, and among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 11 of the major companies involved in the Anti-infective Vaccines Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the anti-infective vaccines market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

ページTOPに戻る

Table of Contents

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Anti-infective Vaccines Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Pandemic Preparedness Driving Anti-Infective Vaccine Growth: A Paradigm Shift in Global Health
3.2.1.2 Increasing Prevalence of New and Re-emerging Infectious Diseases
3.2.1.3 Rising Demand for Tailored Vaccination Strategies is Driving Market Expansion
3.2.2 Market Restraining Factors
3.2.2.1 Substantial Expense of Immunization Vaccines Presents Notable Hindrances
3.2.2.2 Lack of Access to Anti-infective Vaccines in Underdeveloped Regions
3.2.3 Market Opportunities
3.2.3.1 Synergistic Collaboration Between Governments, International Health Organizations, and Vaccine Manufacturers
3.2.3.2 Increasing Funding Catalysing Advances in Vaccines and Infectious Disease Research
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis

4 Anti-infective Vaccines Market Analysis by Vaccine Type
4.1 Key Findings
4.2 Vaccine Type Segment: Market Attractiveness Index
4.3 Anti-infective Vaccines Market Size Estimation and Forecast by Vaccine Type
4.4 Seasonal Influenza
4.4.1 Market Size by Region, 2023-2033 (US$ Million)
4.4.2 Market Share by Region, 2023 & 2033 (%)
4.5 Shingles
4.5.1 Market Size by Region, 2023-2033 (US$ Million)
4.5.2 Market Share by Region, 2023 & 2033 (%)
4.6 TdaP Containing /DTaP primary
4.6.1 Market Size by Region, 2023-2033 (US$ Million)
4.6.2 Market Share by Region, 2023 & 2033 (%)
4.7 Pneumococcal Conjugate Vaccine (PCV)
4.7.1 Market Size by Region, 2023-2033 (US$ Million)
4.7.2 Market Share by Region, 2023 & 2033 (%)
4.8 Human Papillomavirus (HPV)
4.8.1 Market Size by Region, 2023-2033 (US$ Million)
4.8.2 Market Share by Region, 2023 & 2033 (%)
4.9 Rotavirus
4.9.1 Market Size by Region, 2023-2033 (US$ Million)
4.9.2 Market Share by Region, 2023 & 2033 (%)
4.10 Varicella
4.10.1 Market Size by Region, 2023-2033 (US$ Million)
4.10.2 Market Share by Region, 2023 & 2033 (%)
4.11 Meningococcal
4.11.1 Market Size by Region, 2023-2033 (US$ Million)
4.11.2 Market Share by Region, 2023 & 2033 (%)
4.12 Other Vaccines
4.12.1 Market Size by Region, 2023-2033 (US$ Million)
4.12.2 Market Share by Region, 2023 & 2033 (%)

5 Anti-infective Vaccines Market Analysis by Application Type
5.1 Key Findings
5.2 Application Type Segment: Market Attractiveness Index
5.3 Anti-infective Vaccines Market Size Estimation and Forecast by Application Type
5.4 Viral
5.4.1 Market Size by Region, 2023-2033 (US$ Million)
5.4.2 Market Share by Region, 2023 & 2033 (%)
5.5 Bacterial
5.5.1 Market Size by Region, 2023-2033 (US$ Million)
5.5.2 Market Share by Region, 2023 & 2033 (%)

6 Anti-infective Vaccines Market Analysis by End-users
6.1 Key Findings
6.2 End-users Segment: Market Attractiveness Index
6.3 Anti-infective Vaccines Market Size Estimation and Forecast by End-users
6.4 Adult Vaccines
6.4.1 Market Size by Region, 2023-2033 (US$ Million)
6.4.2 Market Share by Region, 2023 & 2033 (%)
6.5 Paediatric Vaccines
6.5.1 Market Size by Region, 2023-2033 (US$ Million)
6.5.2 Market Share by Region, 2023 & 2033 (%)
6.6 Wide Ranging (Comprehensive) Vaccines
6.6.1 Market Size by Region, 2023-2033 (US$ Million)
6.6.2 Market Share by Region, 2023 & 2033 (%)

7 Anti-infective Vaccines Market Analysis by Region
7.1 Key Findings
7.2 Regional Market Size Estimation and Forecast

8 North America Anti-infective Vaccines Market Analysis
8.1 Key Findings
8.2 North America Anti-infective Vaccines Market Attractiveness Index
8.3 North America Anti-infective Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
8.4 North America Anti-infective Vaccines Market Size Estimation and Forecast by Country
8.5 North America Anti-infective Vaccines Market Size Estimation and Forecast by Vaccine Type
8.6 North America Anti-infective Vaccines Market Size Estimation and Forecast by Application Type
8.7 North America Anti-infective Vaccines Market Size Estimation and Forecast by End-users
8.8 U.S. Anti-infective Vaccines Market Analysis
8.9 Canada Anti-infective Vaccines Market Analysis

9 Europe Anti-infective Vaccines Market Analysis
9.1 Key Findings
9.2 Europe Anti-infective Vaccines Market Attractiveness Index
9.3 Europe Anti-infective Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
9.4 Europe Anti-infective Vaccines Market Size Estimation and Forecast by Country
9.5 Europe Anti-infective Vaccines Market Size Estimation and Forecast by Vaccine Type
9.6 Europe Anti-infective Vaccines Market Size Estimation and Forecast by Application Type
9.7 Europe Anti-infective Vaccines Market Size Estimation and Forecast by End-users
9.8 Germany Anti-infective Vaccines Market Analysis
9.9 France Anti-infective Vaccines Market Analysis
9.10 UK Anti-infective Vaccines Market Analysis
9.11 Italy Anti-infective Vaccines Market Analysis
9.12 Spain Anti-infective Vaccines Market Analysis
9.13 Russia Anti-infective Vaccines Market Analysis
9.14 Rest of Europe Anti-infective Vaccines Market Analysis

10 Asia Pacific Anti-infective Vaccines Market Analysis
10.1 Key Findings
10.2 Asia Pacific Anti-infective Vaccines Market Attractiveness Index
10.3 Asia Pacific Anti-infective Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
10.4 Asia Pacific Anti-infective Vaccines Market Size Estimation and Forecast by Country
10.5 Asia Pacific Anti-infective Vaccines Market Size Estimation and Forecast by Vaccine Type
10.6 Asia Pacific Anti-infective Vaccines Market Size Estimation and Forecast by Application Type
10.7 Asia Pacific Anti-infective Vaccines Market Size Estimation and Forecast by End-users
10.8 Japan Anti-infective Vaccines Market Analysis
10.9 China Anti-infective Vaccines Market Analysis
10.10 India Anti-infective Vaccines Market Analysis
10.11 Australia Anti-infective Vaccines Market Analysis
10.12 South Korea Anti-infective Vaccines Market Analysis
10.13 Singapore Anti-infective Vaccines Market Analysis
10.14 Rest of Asia Pacific Anti-infective Vaccines Market Analysis

11 Latin America Anti-infective Vaccines Market Analysis
11.1 Key Findings
11.2 Latin America Anti-infective Vaccines Market Attractiveness Index
11.3 Latin America Anti-infective Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
11.4 Latin America Anti-infective Vaccines Market Size Estimation and Forecast by Country
11.5 Latin America Anti-infective Vaccines Market Size Estimation and Forecast by Vaccine Type
11.6 Latin America Anti-infective Vaccines Market Size Estimation and Forecast by Application Type
11.7 Latin America Anti-infective Vaccines Market Size Estimation and Forecast by End-users
11.8 Brazil Anti-infective Vaccines Market Analysis
11.9 Mexico Anti-infective Vaccines Market Analysis
11.10 Argentina Anti-infective Vaccines Market Analysis
11.11 Colombia Anti-infective Vaccines Market Analysis
11.12 Rest of Latin America Anti-infective Vaccines Market Analysis

12 MEA Anti-infective Vaccines Market Analysis
12.1 Key Findings
12.2 MEA Anti-infective Vaccines Market Attractiveness Index
12.3 MEA Anti-infective Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
12.4 MEA Anti-infective Vaccines Market Size Estimation and Forecast by Country
12.5 MEA Anti-infective Vaccines Market Size Estimation and Forecast by Vaccine Type
12.6 MEA Anti-infective Vaccines Market Size Estimation and Forecast by Application Type
12.7 MEA Anti-infective Vaccines Market Size Estimation and Forecast by End-users
12.8 GCC Anti-infective Vaccines Market Analysis
12.9 South Africa Anti-infective Vaccines Market Analysis
12.10 Rest of MEA Anti-infective Vaccines Market Analysis

13 Company Profiles
13.1 Competitive Landscape, 2022
13.2 Strategic Outlook
13.1 Pfizer Inc.
13.1.1 Company Snapshot
13.1.2 Company Overview
13.1.3 Financial Analysis
13.1.3.1 Net Revenue, 2017-2022
13.1.3.2 R&D, 2017-2022
13.1.3.3 Regional Market Shares, 2022
13.1.4 Product Benchmarking
13.1.5 Strategic Outlook
13.2 AstraZeneca
13.2.1 Company Snapshot
13.2.2 Company Overview
13.2.3 Financial Analysis
13.2.3.1 Net Revenue, 2017-2022
13.2.3.2 R&D, 2017-2022
13.2.3.3 Regional Market Shares, 2022
13.2.4 Product Benchmarking
13.2.5 Strategic Outlook
13.3 Bavarian Nordic
13.3.1 Company Snapshot
13.3.2 Company Overview
13.3.3 Financial Analysis
13.3.3.1 Net Revenue, 2017-2022
13.3.3.2 R&D, 2017-2022
13.3.3.3 Regional Market Shares, 2022
13.3.4 Product Benchmarking
13.3.5 Strategic Outlook
13.4 Serum Institute of India Pvt. Ltd.
13.4.1 Company Snapshot
13.4.2 Company Overview
13.4.3 Product Benchmarking
13.4.4 Strategic Outlook
13.5 BioDiem
13.5.1 Company Snapshot
13.5.2 Company Overview
13.5.3 Product Benchmarking
13.6 Evotec SE
13.6.1 Company Snapshot
13.6.2 Company Overview
13.6.3 Financial Analysis
13.6.3.1 Net Revenue, 2017-2022
13.6.3.2 R&D, 2017-2022
13.6.3.3 Regional Market Shares, 2022
13.6.4 Product Benchmarking
13.6.5 Strategic Outlook
13.7 Sinovac
13.7.1 Company Snapshot
13.7.2 Company Overview
13.7.3 Financial Analysis
13.7.3.1 Net Revenue, 2017-2022
13.7.3.2 R&D, 2017-2022
13.7.4 Product Benchmarking
13.7.5 Strategic Outlook
13.8 Sanofi
13.8.1 Company Snapshot
13.8.2 Company Overview
13.8.3 Product Benchmarking
13.8.4 Strategic Outlook
13.9 Merck KGaA
13.9.1 Company Snapshot
13.9.2 Company Overview
13.9.3 Financial Analysis
13.9.3.1 Net Revenue, 2017-2022
13.9.3.2 R&D, 2017-2022
13.9.3.3 Regional Market Shares, 2022
13.9.4 Product Benchmarking
13.9.5 Strategic Outlook
13.10 CSL
13.10.1 Company Snapshot
13.10.2 Company Overview
13.10.3 Financial Analysis
13.10.3.1 Net Revenue, 2017-2022
13.10.3.2 R&D, 2017-2022
13.10.3.3 Regional Market Shares, 2022
13.10.4 Product Benchmarking
13.10.5 Strategic Outlook
13.11 Emergent
13.11.1 Company Snapshot
13.11.2 Company Overview
13.11.3 Financial Analysis
13.11.3.1 Net Revenue, 2017-2022
13.11.3.2 R&D, 2017-2022
13.11.4 Product Benchmarking
13.11.5 Strategic Outlook
13.12 Mitsubishi Tanabe Pharma Corporation
13.12.1 Company Snapshot
13.12.2 Company Overview
13.12.3 Product Benchmarking
13.12.4 Strategic Outlook
13.13 GSK plc
13.13.1 Company Snapshot
13.13.2 Company Overview
13.13.3 Financial Analysis
13.13.3.1 Net Revenue, 2017-2022
13.13.3.2 R&D, 2017-2022
13.13.3.3 Regional Market Shares, 2022
13.13.4 Product Benchmarking
13.13.5 Strategic Outlook
13.14 Valneva SE
13.14.1 Company Snapshot
13.14.2 Company Overview
13.14.3 Financial Analysis
13.14.3.1 Net Revenue, 2017-2022
13.14.3.2 R&D, 2017-2022
13.14.3.3 Regional Market Shares, 2022
13.14.4 Product Benchmarking
13.14.5 Strategic Outlook
13.15 Novavax
13.15.1 Company Snapshot
13.15.2 Company Overview
13.15.3 Financial Analysis
13.15.3.1 Net Revenue, 2017-2022
13.15.3.2 R&D, 2017-2022
13.15.3.3 Regional Market Shares, 2022
13.15.4 Product Benchmarking
13.15.5 Strategic Outlook

14 Conclusion and Recommendations
14.1 Concluding Remarks from Visiongain
14.2 Recommendations for Market Players

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1 Anti-infective Vaccines Market Snapshot, 2023 & 2033 (US$ Million, CAGR %)
Table 2 Anti-infective Vaccines Market Forecast by Region 2023-2033 (US$ Million, AGR%, CAGR%): "V" Shaped Recovery
Table 3 Anti-infective Vaccines Market Forecast by Region 2023-2033 (US$ Million, AGR%, CAGR%): "U" Shaped Recovery
Table 4 Anti-infective Vaccines Market Forecast by Region 2023-2033 (US$ Million, AGR%, CAGR%): "W" Shaped Recovery
Table 5 Anti-infective Vaccines Market Forecast by Region 2023-2033 (US$ Million, AGR%, CAGR%): "L" Shaped Recovery
Table 6 Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 7 Seasonal Influenza Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 8 Shingles Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 9 TdaP Containing/ DTaP Primary Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 10 Pneumococcal Conjugate Vaccine (PCV) Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 11 Human Papillomavirus (HPV) Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 12 Rotavirus Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 13 Varicella Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 14 Meningococcal Vaccine Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 15 Other Vaccine Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 16 Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 17 Viral Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 18 Bacterial Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 19 Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 20 Adult Vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 21 Paediatric Vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 22 Wide-ranging (comprehensive) vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 23 Anti-infective Vaccines Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 24 North America Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 25 North America Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 26 North America Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 27 North America Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 28 U.S. Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 29 Canada Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 30 Europe Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR %)
Table 31 Europe Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 32 Europe Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 33 Europe Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 34 Germany Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 35 France Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 36 UK Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 37 Italy Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 38 Spain Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 39 Russia Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 40 Rest of Europe Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 41 Asia Pacific Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 42 Asia Pacific Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 43 Asia Pacific Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 44 Asia Pacific Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 45 Japan Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 46 China Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 47 India Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 48 Australia Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 49 South Korea Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 50 Singapore Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 51 Rest of Asia Pacific Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 52 Latin America Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 53 Latin America Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 54 Latin America Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 55 Latin America Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 56 Brazil Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 57 Mexico Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 58 Argentina Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 59 Colombia Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 60 Rest of Latin America Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 61 MEA Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 62 MEA Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 63 MEA Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 64 MEA Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 65 GCC Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 66 South Africa Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 67 Rest of MEA Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 68 Strategic Outlook
Table 69 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 70 Pfizer Inc.: Product Benchmarking
Table 71 Pfizer: Strategic Outlook
Table 72 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 73 AstraZeneca: Product Benchmarking
Table 74 AstraZeneca: Strategic Outlook
Table 75 Bavarian Nordic: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 76 Bavarian Nordic: Product Benchmarking
Table 77 Bavarian Nordic: Strategic Outlook
Table 78 Serum Institute of India Pvt. Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 79 Serum Institute of India Pvt. Ltd.: Product Benchmarking
Table 80 Serum Institute of India Pvt. Ltd.: Strategic Outlook
Table 81 BioDiem: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 82 BioDiem: Product Benchmarking
Table 83 Evotec SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 84 Evotec SE: Product Benchmarking
Table 85 Evotec SE: Strategic Outlook
Table 86 Sinovac: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 87 Sinovac: Product Benchmarking
Table 88 Sinovac: Strategic Outlook
Table 89 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 90 Sanofi: Product Benchmarking
Table 91 Sanofi: Strategic Outlook
Table 92 Merck KGaA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 Merck KGaA: Product Benchmarking
Table 94 Merck: Strategic Outlook
Table 95 CSL: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 CSL: Product Benchmarking
Table 97 CSL: Strategic Outlook
Table 98 Emergent: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 99 Emergent: Product Benchmarking
Table 100 Emergent: Strategic Outlook
Table 101 Mitsubishi Tanabe Pharma Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 102 Mitsubishi Tanabe Pharma Corporation: Product Benchmarking
Table 103 Mitsubishi Tanabe Pharma Corporation: Strategic Outlook
Table 104 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 GSK plc: Product Benchmarking
Table 106 GSK: Strategic Outlook
Table 107 Valneva SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 108 Valneva SE: Product Benchmarking
Table 109 Valneva SE: Strategic Outlook
Table 110 Novavax: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 111 Novavax: Product Benchmarking
Table 112 Novavax: Strategic Outlook

List of Figures
Figure 1 Anti-infective Vaccines Market Segmentation
Figure 2 Anti-infective Vaccines Market by Vaccine Type: Market Attractiveness Index
Figure 3 Anti-infective Vaccines Market by Application Type: Market Attractiveness Index
Figure 4 Anti-infective Vaccines Market by End-users: Market Attractiveness Index
Figure 5 Anti-infective Vaccines Market Attractiveness Index by Region
Figure 6 Anti-infective Vaccines Market: Market Dynamics
Figure 7 Anti-infective Vaccines Market by Region, 2023-2033 (US$ Million, AGR %): “V” Shaped Recovery
Figure 8 Anti-infective Vaccines Market by Region, 2023-2033 (US$ Million, AGR %): “U” Shaped Recovery
Figure 9 Anti-infective Vaccines Market by Region, 2023-2033 (US$ Million, AGR %): “W” Shaped Recovery
Figure 10 Anti-infective Vaccines Market by Region, 2023-2033 (US$ Million, AGR %): “L” Shaped Recovery
Figure 11 Anti-infective Vaccines Market: Porter’s Five Forces Analysis
Figure 12 Anti-infective Vaccines Market: PEST Analysis
Figure 13 Anti-infective Vaccines Market by Vaccine Type: Market Attractiveness Index
Figure 14 Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
Figure 15 Anti-infective Vaccines Market Share Forecast by Vaccine Type, 2023, 2028, 2033 (%)
Figure 16 Seasonal Influenza Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 17 Seasonal Influenza Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 18 Shingles Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 19 Shingles Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 20 TdaP Containing/ DTaP Primary Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 21 TdaP Containing/ DTaP Primary Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 22 Pneumococcal Conjugate Vaccine (PCV) Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 23 Pneumococcal Conjugate Vaccine (PCV) Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 24 Human Papillomavirus (HPV) Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 25 Human Papillomavirus (HPV) Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 26 Rotavirus Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 27 Rotavirus Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 28 Varicella Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 29 Varicella Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 30 Meningococcal Vaccine Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 31 Meningococcal Vaccine Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 32 Other Vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 33 Other Vaccines Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 34 Anti-infective Vaccines Market by Application Type: Market Attractiveness Index
Figure 35 Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR %)
Figure 36 Anti-infective Vaccines Market Share Forecast by Application Type, 2023, 2028, 2033 (%)
Figure 37 Viral Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 38 Viral Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 39 Bacterial Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 40 Bacterial Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 41 Anti-infective Vaccines Market by End-users: Market Attractiveness Index
Figure 42 Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
Figure 43 Anti-infective Vaccines Market Share Forecast by End-users, 2023, 2028, 2033 (%)
Figure 44 Adult Vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 45 Adult Vaccines Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 46 Paediatric Vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 47 Paediatric Vaccines Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 48 Wide-ranging (comprehensive) vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 49 Wide-ranging comprehensive vaccines Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 50 Anti-infective Vaccines Market Forecast by Region 2023 and 2033 (Revenue, CAGR%)
Figure 51 Anti-infective Vaccines Market Share Forecast by Region 2023, 2028, 2033 (%)
Figure 52 Anti-infective Vaccines Market by Region, 2023-2033 (US$ Million, AGR %)
Figure 53 North America Anti-infective Vaccines Market Attractiveness Index
Figure 54 North America Anti-infective Vaccines Market by Region, 2023, 2028 & 2033 (US$ Million)
Figure 55 North America Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
Figure 56 North America Anti-infective Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
Figure 57 North America Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
Figure 58 North America Anti-infective Vaccines Market Share Forecast by Vaccine Type, 2023 & 2033 (%)
Figure 59 North America Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR %)
Figure 60 North America Anti-infective Vaccines Market Share Forecast by Application Type, 2023 & 2033 (%)
Figure 61 North America Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
Figure 62 North America Anti-infective Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
Figure 63 U.S. Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 64 Canada Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 65 Europe Anti-infective Vaccines Market Attractiveness Index
Figure 66 Europe Anti-infective Vaccines Market by Region, 2023, 2028 & 2033 (US$ Million)
Figure 67 Europe Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
Figure 68 Europe Anti-infective Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
Figure 69 Europe Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
Figure 70 Europe Anti-infective Vaccines Market Share Forecast by Vaccine Type, 2023 & 2033 (%)
Figure 71 Europe Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR %)
Figure 72 Europe Anti-infective Vaccines Market Share Forecast by Application Type, 2023 & 2033 (%)
Figure 73 Europe Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
Figure 74 Europe Anti-infective Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
Figure 75 Germany Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 76 France Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 77 UK Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 78 Italy Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 79 Spain Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 80 Russia Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 81 Rest of Europe Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 82 Asia Pacific Anti-infective Vaccines Market Attractiveness Index
Figure 83 Asia Pacific Anti-infective Vaccines Market by Region, 2023, 2028 & 2033 (US$ Million)
Figure 84 Asia Pacific Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
Figure 85 Asia Pacific Anti-infective Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
Figure 86 Asia Pacific Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
Figure 87 Asia Pacific Anti-infective Vaccines Market Share Forecast by Vaccine Type, 2023 & 2033 (%)
Figure 88 Asia Pacific Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR %)
Figure 89 Asia Pacific Anti-infective Vaccines Market Share Forecast by Application Type, 2023 & 2033 (%)
Figure 90 Asia Pacific Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
Figure 91 Asia Pacific Anti-infective Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
Figure 92 Japan Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 93 China Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 94 India Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 95 Australia Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 96 South Korea Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 97 Singapore Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 98 Rest of Asia Pacific Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 99 Latin America Anti-infective Vaccines Market Attractiveness Index
Figure 100 Latin America Anti-infective Vaccines Market by Region, 2023, 2028 & 2033 (US$ Million)
Figure 101 Latin America Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
Figure 102 Latin America Anti-infective Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
Figure 103 Latin America Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
Figure 104 Latin America Anti-infective Vaccines Market Share Forecast by Vaccine Type, 2023 & 2033 (%)
Figure 105 Latin America Anti-infective Vaccines Market Forecast by Usage Type, 2023-2033 (US$ Million, AGR %)
Figure 106 Latin America Anti-infective Vaccines Market Share Forecast by Application Type, 2023 & 2033 (%)
Figure 107 Latin America Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
Figure 108 Latin America Anti-infective Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
Figure 109 Brazil Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 110 Mexico Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 111 Argentina Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 112 Colombia Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 113 Rest of Latin America Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 114 MEA Anti-infective Vaccines Market Attractiveness Index
Figure 115 MEA Anti-infective Vaccines Market by Region, 2023, 2028 & 2033 (US$ Million)
Figure 116 MEA Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
Figure 117 MEA Anti-infective Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
Figure 118 MEA Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
Figure 119 MEA Anti-infective Vaccines Market Share Forecast by Vaccine Type, 2023 & 2033 (%)
Figure 120 MEA Anti-infective Vaccines Market Forecast by Usage Type, 2023-2033 (US$ Million, AGR %)
Figure 121 MEA Anti-infective Vaccines Market Share Forecast by Application Type, 2023 & 2033 (%)
Figure 122 MEA Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
Figure 123 MEA Anti-infective Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
Figure 124 GCC Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 125 South Africa Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 126 Rest of MEA Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 127 Pfizer Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 128 Pfizer Inc.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 129 Pfizer Inc.: Regional Market Shares, 2022
Figure 130 AstraZeneca: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 131 AstraZeneca: R&D, 2017-2022 (US$ Million, AGR%)
Figure 132 AstraZeneca: Regional Market Shares, 2022
Figure 133 Bavarian Nordic: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 134 Bavarian Nordic: R&D, 2017-2022 (US$ Million, AGR%)
Figure 135 AstraZeneca: Regional Market Shares, 2022
Figure 136 Evotec SE: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 137 Evotec SE: R&D, 2017-2022 (US$ Million, AGR%)
Figure 138 Evotec: Regional Market Shares, 2022
Figure 139 Sinovac: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 140 Sinovac: R&D, 2017-2022 (US$ Million, AGR%)
Figure 141 Merck KGaA: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 142 Merck KGaA: R&D, 2017-2022 (US$ Million, AGR%)
Figure 143 Merck KGaA: Regional Market Shares, 2022
Figure 144 CSL: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 145 CSL: R&D, 2017-2022 (US$ Million, AGR%)
Figure 146 CSL: Regional Market Shares, 2022
Figure 147 Emergent: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 148 Emergent: R&D, 2017-2022 (US$ Million, AGR%)
Figure 149 GSK plc: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 150 GSK plc: R&D, 2017-2022 (US$ Million, AGR%)
Figure 151 GSK plc: Regional Market Shares, 2022
Figure 152 Valneva SE: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 153 Valneva SE: R&D, 2017-2022 (US$ Million, AGR%)
Figure 154 Valneva SE: Regional Market Shares, 2022
Figure 155 Novavax: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 156 Novavax: R&D, 2017-2022 (US$ Million, AGR%)
Figure 157 Novavax: Regional Market Shares, 2022

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

本レポートと同分野の最新刊レポートはありません。

Visiongain 社の最新刊レポート

本レポートと同じKEY WORD（vaccines market）の最新刊レポート

よくあるご質問

Visiongain社はどのような調査会社ですか?

英国の調査会社ヴィジョンゲイン社（Visiongain）は、通信とエネルギーのほか、自動車や化学・医薬品、金属など、広範な市場を対象に調査を行っています。自動車市場については、市場全般に関する調査のほ... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

抗感染症ワクチン市場レポート：2023-2033

サマリー

目次

図表リスト

Summary

Table of Contents

List of Tables/Graphs

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野の最新刊レポート

Visiongain 社の最新刊レポート

本レポートと同じKEY WORD（vaccines market）の最新刊レポート

よくあるご質問

Visiongain社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?